| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
Purity: ≥98%
Fusidic Acid (Fucidin; SQ-16603), a bacteriostatic antibiotic isolated from the Fusidium coccineum fungus, is a protein synthesis inhibitor of the steroidal class used to treat bacterial infections. It acts by inhibiting translocation during protein synthesis.
| Targets |
Bacterial
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
The oral bioavailability of fusidic acid sodium tablets is 91%. Film-coated tablets are absorbed completely compared to solutions, but individual differences exist in oral absorption. In pediatric patients, the bioavailability of fusidic acid hemihydrate (suspension) after oral administration of a dose of 20 mg/kg is 22.5%. Metabolites/Metabolites Metabolites include dicarboxylic acid esters/acids, 3-ketofusidic acid, hydroxyfusidic acid, glucuronic acid fusidic acid, and an ethylene glycol metabolite. Biological Half-Life Approximately 5 to 6 hours in adults. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Fusidic acid has not yet received marketing approval from the U.S. Food and Drug Administration (FDA), but topical and systemic formulations are available in other countries. Data on fusidic acid excretion in breast milk is outdated and not from rigorously designed studies, but the concentration of the drug in breast milk appears to be low after intravenous fusidic acid administration. When using topical products, ensure that the infant's skin does not come into direct contact with the treated area. Water-soluble creams or gels should only be applied to the breasts, as ointments may expose the infant to high concentrations of mineral oil through licking. Topical application of fusidic acid appears to be relatively ineffective for treating nipple pain and cracking. ◉ Effects on Breastfed Infants As of the revision date, no published information was found. ◉ Effects on Lactation and Breast Milk A small, randomized, non-blinded trial in mothers with nipple pain and cracking showed that applying fusidic acid ointment to the nipples after each breastfeeding session was far less effective than oral antibiotics (cloxacillin or erythromycin, for 10 days) (36% vs 79%). Furthermore, 43% of patients did not experience symptom improvement after using fusidic acid, compared to 16% in the oral antibiotic group; 21% of patients experienced worsening symptoms after using fusidic acid, compared to 5% in the oral antibiotic group. Protein Binding Rate 97% to 99% |
| References |
|
| Additional Infomation |
Fusidic acid is a steroidal antibiotic isolated from the fermentation broth of Fusidium coccineum. It is a protein synthesis inhibitor, a pantothenic acid kinase (EC 2.7.1.33) inhibitor, and a metabolite of Escherichia coli. It is a 3α-hydroxysteroid, 11α-hydroxysteroid, sterol ester, steroidal acid, α,β-unsaturated monocarboxylic acid, and steroidal antibiotic. It is the conjugate acid of fusidic acid, derived from the hydrogenation of 5α-cholestane.
An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th edition) Its mechanism of action is through inhibiting translocation during protein synthesis. It is commonly used in topical formulations such as creams and eye drops, but systemic formulations such as tablets and injections are also available. Fusidic acid has been reported in Stilbella aciculosa, Microsporum canis, and other microorganisms for which relevant data are available. Fusidic acid is an antibacterial antibiotic extracted from Clostridium coccineum and used topically to treat skin infections. Fusidic acid inhibits bacterial protein synthesis by preventing the detachment of elongation factor G (EF-G) from the ribosome. Fusidic acid is primarily effective against Gram-positive bacteria. It is an antibiotic isolated from the fermentation broth of Clostridium coccineum. (From Merck Index, 11th edition) It works by inhibiting translocation during protein synthesis. See also: Sodium fusidic acid (active ingredient). Indications: For the treatment of bacterial infections. Mechanism of Action: Fusidic acid works by interfering with bacterial protein synthesis; specifically, it works by preventing the translocation of elongation factor G (EF-G) from the ribosome. It also inhibits chloramphenicol acetyltransferase. |
| Molecular Formula |
C31H48O6
|
|---|---|
| Molecular Weight |
516.7092
|
| Exact Mass |
516.345
|
| Elemental Analysis |
C, 72.06; H, 9.36; O, 18.58
|
| CAS # |
6990-06-3
|
| Related CAS # |
Fusidic acid sodium salt;751-94-0;Fusidic acid-d6
|
| PubChem CID |
3000226
|
| Appearance |
Solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
635.6±55.0 °C at 760 mmHg
|
| Melting Point |
190-192ºC
|
| Flash Point |
197.7±25.0 °C
|
| Vapour Pressure |
0.0±4.2 mmHg at 25°C
|
| Index of Refraction |
1.558
|
| LogP |
6.41
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
994
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O([H])[C@]1([H])C([H])([H])[C@@]2([H])/C(=C(/C(=O)O[H])\C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])/[C@]([H])(C([H])([H])[C@]2(C([H])([H])[H])[C@@]2(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]3([H])[C@]([H])(C([H])([H])[H])[C@@]([H])(C([H])([H])C([H])([H])[C@]3(C([H])([H])[H])[C@@]21[H])O[H])OC(C([H])([H])[H])=O
|
| InChi Key |
IECPWNUMDGFDKC-CDSRIIBBSA-N
|
| InChi Code |
InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21?,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
|
| Chemical Name |
(Z)-2-((3R,4S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-enoic
acid
|
| Synonyms |
Anhydrous Fusidic Acid; Fucidin; Fucidine; SQ-16603; CEM-102; SQ 16603; CEM 102; SQ16603; CEM102
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~193.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (4.84 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9353 mL | 9.6766 mL | 19.3532 mL | |
| 5 mM | 0.3871 mL | 1.9353 mL | 3.8706 mL | |
| 10 mM | 0.1935 mL | 0.9677 mL | 1.9353 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05353374 | Completed | Drug: Sodium Fusidate 2 % Topical Ointment Drug: Petrolatum ointment |
Acrochordon Seborrheic Keratosis |
Indonesia University | 2021-01-01 | Not Applicable |
| NCT02569541 | Completed | Drug: sodium fusidate | Refractory Bone or Joint Infections | Arrevus Inc. | 2015-12 | Phase 2 Phase 3 |
| NCT00986856 | Terminated | Drug: Fucidin® cream | Impetigo | LEO Pharma | 2004-05 | Phase 4 |
| NCT03105505 | Unknown status | Drug: Permethrin 5% Drug: Synthomycine 5% Drug: Fusidic Acid 1% M/R Eye Drops |
Inflammation of the Eyelids | Barzilai Medical Center | 2017-04-28 | Phase 4 |
| NCT06695143 | Not yet recruiting | Drug: Fusidic Acid Other: Vehicle cream |
Leishmaniasis, Cutaneous | Institute of Tropical Medicine, Belgium | 2025-04 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA